ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: SA-PO1083

Effect of Prolonged-Release vs. Immediate-Release Tacrolimus on Neurocognition in Kidney Transplant Recipients: A Pilot Randomized Controlled Trial (RCT)

Session Information

Category: Transplantation

  • 2102 Transplantation: Clinical

Authors

  • Lala Gul, Hadia, UC Davis Health, Sacramento, California, United States
  • Sockolov, Macey, UC Davis Health, Sacramento, California, United States
  • Kaur, Amanpreet, UC Davis Health, Sacramento, California, United States
  • Occhipinti, Michelle, UC Davis Health, Sacramento, California, United States
  • Bang, Heejung, UC Davis Health, Sacramento, California, United States
  • Alnimri, Muna, UC Davis Health, Sacramento, California, United States
  • Huang, Yihung, UC Davis Health, Sacramento, California, United States
  • Chen, Ling-Xin, UC Davis Health, Sacramento, California, United States
  • Howes, Katherine A., UC Davis Health, Sacramento, California, United States
Background

Tacrolimus is known to cause neurological side effects and elderly individuals seem particularly vulnerable. It is unknown if the prolonged-release (PR) tacrolimus (Envarsus XR) formulation minimizes neurocognitive side effects compared to immediate release (IR) tacrolimus due to lower peak serum levels. We aimed to compare the neurocognitive side effects of PR and IR tacrolimus in elderly kidney transplant recipients within the first months post-transplantation.

Methods

In this single center, prospective, open-label, randomized trial, 64 kidney transplant recipients aged 60 or above were randomized to PR tacrolimus or IR tacrolimus between 4 and 8 weeks post-transplantation and followed for 6 weeks. Neurocognitive performance was assessed by the Montreal Cognitive Assessment (MOCA) and Digit Symbol Substitution Test (DSST). Secondary outcomes of tremor and quality of life were assessed through the Quality of Life in Essential Tremor Questionnaire (QUEST) and Organ Transplant Symptom and Wellbeing Instrument (OTSWI).

Results

32 patients were randomized to the IR tacrolimus arm and 31 into the PR tacrolimus arm. Mean age was 69 in both arms and 37% were women. Table 1 shows the assessment scores for the primary and secondary outcomes. There was no statistically significant difference between groups in the change in MOCA or DSST scores from baseline to 6 weeks or in tremor or quality of life measures.

Conclusion

Although prior studies indicated improvement in neurological side effects in PR tacrolimus compared with IR tacrolimus, the improvement does not appear to extend to neurocognitive side effects as assessed by the MOCA or DSST tests in this cohort.

Table 1. Neurocognitive Testing and Tremor Results. P-values were computed from ANCOVA adjusting baseline value and without adjusting for multiplicity. Values shown are mean and (standard deviation).

Funding

  • Commercial Support – Veloxis Pharmaceuticals, Inc